European consensus on the histopathology of inflammatory bowel diseas by Magro, F et al.
Available at:
http://hdl.handle.net/2078.1/156332
[Downloaded 2019/04/19 at 07:12:38 ]
"European consensus on the histopathology
of inflammatory bowel diseas"
Magro, F ; Langner, C ; Driessen, A ; Ensari, A ; Geboes, K ; Mantzaris, G J ; Villanacci,
V ; Becheanu, G ; Borralho Nunes, P ; Cathomas, G ; Fries, W ; Jouret-Mourin, Anne ;
Mescoli, C ; de Petris, G ; Rubio, C A ; Shepherd, N A ; Vieth, M ; Eliakim, R ; European
Society of Pathology (ESP) ; European Crohn's and Colitis Organisation (ECCO)
Abstract
The histologic examination of endoscopic biopsies or resection specimens
remains a key step in the work-up of affected inflammatory bowel disease (IBD)
patients and can be used for diagnosis and differential diagnosis, particularly
in the differentiation of UC from CD and other non-IBD related colitides. The
introduction of new treatment strategies in inflammatory bowel disease (IBD)
interfering with the patients' immune system may result in mucosal healing,
making the pathologists aware of the impact of treatment upon diagnostic
features. The European Crohn's and Colitis Organisation (ECCO) and the
European Society of Pathology (ESP) jointly elaborated a consensus to establish
standards for histopathology diagnosis in IBD. The consensus endeavors to
address: (i) procedures required for a proper diagnosis, (ii) features which can be
used for the analysis of endoscopic biopsies, (iii) features which can be used for
the analysis of surgical samples, (iv) criteria for diagnosis and diff...
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1. Introduction
Inflammatory bowel diseases (IBD) are lifelong disorders that
are predominantly observed in developed countries and arise
from an interaction between genetic and environmental fac-
tors. The term IBD was coined to cover two specific diseases:
ulcerative colitis (UC) and Crohn's disease (CD). During the last
25 years, several elements have influenced the accuracy of
histologic IBD diagnosis. The widespread introduction of endos-
copy allowed the analysis of multiple mucosal biopsies from
different segments of the colon, ileum and other parts of the
gastrointestinal tract. The precise etiology of IBD is unknown
and therefore a causal therapy to cure the disease is not yet
available. However, the introduction of new treatment strate-
gies interfering with the patients' immune systemmay result in
mucosal healing, making the pathologists aware of the impact
of treatment upon diagnostic features.
The Consensus initiated by the European Crohn's and Colitis
Organization (ECCO) and the European Society of Pathology
(ESP) endeavors to address the different aspects of histologic
diagnosis in IBD: (i) procedures required for a proper diagnosis,
(ii) features which can be used for the analysis of endoscopic
biopsies, (iii) features which can be used for the analysis of
surgical samples, (iv) criteria for diagnosis and differential
diagnosis and (v) special situations including those inherent to
therapy questions that are addressed include: how many
features should be present for a firm diagnosis? What is the
role of histology in patient management, including search for
dysplasia? Which features if any, can be used for assessment of
disease activity?
The aim of the Consensus is to propose European Guidelines
for the histopathological diagnosis of chronic colitides. The
document is based, in parts, upon previous evidence-based
ECCO consensus publications on the diagnosis andmanagement
of UC and CD.1,2 On September 11th 2012, in Prague, these
guidelines were revised at a meeting of ECCO GuiCom and ESP
representatives, at the annual European Congress of Pathology
(ECP).
The strategy to reach the Consensus involved six steps: four
working groups (WGs) were formed each comprising three ESP
delegates and one ECCO delegate:WG 1 was on UC (chaired by
Ann Driessen and Gerassimos Mantzaris), WG 2 on CD (chaired
by Cord Langner and Fernando Magro), WG3 on lymphocytic
and collagenous colitis (chaired by Arzu Ensari and Vicenzo
Villanacci) and WG 4 was on indeterminate, unclassified and
infectious colitis related to IBD (chaired by Karel Geboes and
Rami Eliakim). The existing ECCO guideline statements refer-
ring to the histologic diagnosis of IBD were analyzed systemat-
ically by the chairs of each WG. Guideline statements selected
for change and questions unresolved in the 2008 and 2010
guidelines were distributed to the WG members. Participants
were asked to answer the questions based on their experience
as well as evidence from the literature (Delphi procedure).3 In
parallel, the WG members performed a systematic literature
search of their topic with the appropriate key words using
Medline/Pubmed/ISI/Scopus and the Cochrane database, as
well as their own files. As a further selection criterion, only
those featureswhich achievedmoderate reproducibility judged
by kappa value, or findings that were confirmed by subsequent
studies, were considered. The evidence level (EL) was graded
according to the Oxford Centre for Evidence-Based Medicine.4
Provisional guideline statements (with supporting text) were
then written by the WG chairs based on answers to the
questionnaire and were circulated among the WG members,
prompting discussions and exchange of literature evidence. On
May 31st 2012 the working party chairs submitted the proposed
statements and the supporting text online on a weblog for
discussion among all other Consensus participants (who have
not been part of that specific WG). All participants then met in
Prague on September 11th 2012 to vote and agree on the final
version of the statements. Consensus was defined as such when
agreement was reached by more than 80% of participants,
termed a Consensus Statement and numbered for convenience
in the document. Each recommendation was graded according
to the Oxford Centre for Evidence Based Medicine based on the
level of evidence.4 All statements achieved 100% agreement,
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with the exception of statements 16, 23, 24 and 32, which
achieved 83–92% agreement.
The final document was written by the WG chairs in
conjunction with theWGmembers. The Consensus participants
agreed to produce two separate publications. One (which will
be published in the Journal of Crohn's and Colitis) summarizes
the statements followed by comments is on the evidence
Special attention is given to the clinico-pathologic interface,
e.g. to technical procedures necessary for accurate diagnosis
of IBD on endoscopic biopsies (number and way of handling of
biopsies etc.). Images are not provided in this paper. The
second publication (in Virchows Archiv) focuses on the
histologic criteria for diagnosis and differential diagnosis
(without the Consensus statements), accompanied by illustra-
tive images. The final text of both publications was approved
by all Consensus participants.
2. Procedures needed for the diagnosis of IBD
The diagnosis of IBD requires a multidisciplinary approach
involving a team of specialists (e.g. gastroenterologists, pathol-
ogists and radiologists). The diagnosis should be established by a
combination of medical history, clinical evaluation, laboratory
data (including negative stool examinations for infectious
agents) and typical endoscopic, histologic and radiologic
findings.2,5 Thus, the histologic examination of endoscopic
biopsies or resection specimens remains a key step in the
work-up of affected patients and can be used for diagnosis and
differential diagnosis, particularly in the differentiation of UC
from CD and other non-IBD related colitides.
ECCO-ESP statement 1
For a reliable diagnosis of inflammatory bowel disease,
ileocolonoscopy rather than rectoscopy should be
performed. A minimum of two biopsies from at least
five sites along the colon, including the rectum, and the
terminal ileum should be obtained [EL 1]. In patients
with fulminant colitis, two samples from at least one
site should be obtained [EL5]. The biopsies should be
collected in separate vials, as localization of the
biopsies gives important diagnostic information
In patients with suspected IBD, it is crucial to perform
a histologic examination before initiation of treatment,
due to changes in morphology induced by certain drugs and
to establish a proper diagnosis. Notably, recent progress
in endoscopic techniques, such as magnifying endoscopy,
chromoendoscopy and/or confocal endomicroscopy has re-
sulted in more punctuate sampling of biopsies, with con-
siderable impact on diagnostic accuracy in the presence of
subtle histologic changes.
The histologic diagnosis of IBD is based on the analysis of a
full series of colonoscopic biopsies. A study by Dejaco et al.6
showed that the accuracy of diagnosing colitis increases from
66% to 92% when segmental biopsies are taken rather than two
biopsies throughout the colon.7 Rectal biopsies are necessary
to either confirm or reject rectal involvement and may
additionally be helpful in differentiating IBD from other
inflammatory lesions. Although the diagnostic accuracy of
total colonoscopy (74%) compared to rectoscopy (64%) is only
slightly higher in UC, cases with atypical distribution of lesions
such as peri-appendiceal inflammation associated with a left-
sided colitis are only detected by this approach.8 Ileoscopy
with biopsies is recommended as an additional step. In
approximately 10–20% of patients with UC the inflammation
may extend into the terminal ileum (backwash-ileitis). The
diagnostic value of terminal ileum biopsies is, however,
highest in patients with known or suspected CD.9,10
During follow-up examinations, a smaller number of biopsy
samples may confirm the diagnosis. In post-surgical follow-up,
biopsies of the neo-terminal ileum are indicated when disease
recurrence is suspected. When patients have undergone ileal
pouch-anal anastomosis, biopsies of the afferent limb are
suggestedwhenCD is suspected. Multiple biopsies are indicated
when the patient is screened for dysplasia (=intraepithelial
neoplasia).
ECCO-ESP statement 2
All tissue samples should be fixed immediately by
immersion in buffered formalin or an equivalent
solution prior to transport [EL5]. Since lesions may
be focal, it is recommended that multiple sections
from each sample are examined [EL2]
Serial sectioning of biopsy specimens is superior to step
sectioning in order to detect mild or focal lesions and to
increase the diagnostic accuracy.11–13 The diagnostic yield
increases with the number of sections examined. However,
the ideal number of sections to be examined in routine
practice has not been established, with numbers varying
between 2 and 6 in different studies.12,14 In routine practice,
step-sections may be the simplest procedure. Obtaining two
or three tissue levels has been proposed, each consisting of
five or more sections.15 This proposal is in agreement with
guidelines proposed by the Austrian, British and German IBD
study groups.16–18 The use of multiple biopsies from different
sites is supported by the expert opinion of clinicians, except
for patients presenting with fulminant colitis. Though the
majority of clinicians will agree to take one or two biopsy
samples from fulminant colitis (from one or two regions), some
clinicians do not perform endoscopy in this setting.
Endoscopic biopsies should be immediately fixed in a
formaldehyde-based fixative or another solution to ascertain
the quality of the material. Biopsies should be stored and
transported in separate vials as this is essential to map and
grade the histologic distribution and degree of inflammation in
different colonic segments and in the terminal ileum. This can
be done by using different containers, multi-well cassettes or
an acetate strip. Orientation of the samples using filter paper
(submucosal side down) before fixation may yield better
results, because it allows a better assessment of architectural
abnormalities. Routine staining with hematoxylin and
eosin is appropriate for diagnosis. Special stains, such as
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immunohistochemistry or other techniques for diagnostic
purposes are not needed routinely.
ECCO-ESP statement 3
The biopsy samples should be accompanied by clinical
information including endoscopic findings as well as the
age of the patient, duration of disease, duration and type
of treatment, comorbidities and travel history [El 5]
IBD diagnosis in patients with diarrhea or rectal bleeding not
only is based on the morphological features observed in
biopsies, but also takes into account background clinical
information, endoscopic findings as well as data from labora-
tory and imaging procedures. Thus, for a reliable diagnosis of
biopsy specimens from patients with suspected IBD detailed
clinical information is inevitable. This information should
include basic demographic data, disease characteristics in-
cluding information on duration of symptoms, co-morbidities,
recent travels, endoscopic findings, or any information
regarding foregone treatment.
ECCO-ESP statement 4
A surgical sample needs complete gross examination,
carried out in an orderly and systematic manner,
including photographic documentation, preferably at
the time when the specimen is removed [EL5]
Surgical samples are opened along the longitudinal axis
(i.e., along the antimesenteric or antimesocolic border,
except at the site of any carcinoma, where it may be advisable
to leave a small segment unopened during fixation). Speci-
mens for microscopy are collected, including lymph nodes,
terminal ileum and appendix.19 The optimum number of
samples from a colectomy specimen that should be obtained
has not been established. However, multiple samples obtained
both from visible lesions and from mucosa which is normal on
gross inspection improve the diagnostic yield. In addition, the
macroscopic aspects and the transmural character of the
disease as well as fistulas can be identified and used for
diagnostic purposes.20,21 Special attention should be paid to
lesions suspicious for neoplasia.
ECCO-ESP statement 5
The pathology report in all chronic colitides should
give an indication of the activity of the disease.
Particularly in Crohn's disease, inactivity in the biopsy
may not reflect inactivity of the disease [EL5]
The healing of mucosal inflammation has already been
noted as a feature of resolution in UC. Biopsies can be used to
discriminate between quiescent disease, inactive disease and
different grades of disease activity. This has led to the
introduction of scoring systems for the assessment of disease
activity in UC and use of these systems in clinical drug trials.22
Adequate number of biopsies should be obtained from not
only grossly inflamed but also normal looking mucosa as mild
or even severe inflammation can be detected in endoscopi-
cally quiescent colitis.23–25 In the study by Kleer et al.24 65% of
the endoscopic and histologic findings were comparable,
whereas in 25% a chronic colitis was diagnosed in biopsies
from an endoscopically normal looking mucosa. In 10% the
opposite was seen.24
In contrast to UC, disease activity is not generally assessed
by pathologists for CD. This is mainly due to the discontinuous
character of the disease, inducing sampling error and the fact
that the ileummay be the only area involved. Sampling error is
very important, especially when only rectal biopsies are
available. Microscopic analysis of multiple samples from
different segments of the colon and ileum may provide useful
information and allow an assessment of disease activity.
Nevertheless, data available on histology and activity for
CD are limited. Several clinical drug trials have shown that
treatment can alter the histology, promoting healing and
normalization of the mucosa.26–31 There is, however, no
general agreement among expert clinicians about the use of
microscopy to assess disease activity. If biopsies are used, then
multiple samples have to be obtained and analyzed. The
presence of epithelial damage in association with neutrophils is
amarker of disease activity.32 Amultivariate logistic regression
model showed that severe lymphocytic (and eosinophilic)
infiltration of the lamina propria, presence of crypt atrophy
and absence of lymphocytic infiltration of the epithelium
are the best variables for predicting uncomplicated
disease.33
ECCO-ESP statement 6
Ileocolonoscopy with biopsies should be performed in
all children or adolescents with suspected IBD [EL2].
Esophagogastroduodenoscopy may improve the diag-
nostic accuracy in the initial diagnostic assessment of
children with possible IBD [EL2]
ECCO-ESP statement 7
The terminology to be used for labeling patientswithout
a definitive diagnosis is unclear [EL1]
Labels such as “indeterminate colitis”, “uncertain colitis”,
“inflammatory bowel disease unclassified (IBDU)”, chronic
inflammatory bowel disease unclassified “CIBD-unclassified”
and “chronic idiopathic inflammatory bowel disease NOS (not
otherwise specified)” are used in the literature for patients
presenting with chronic colitis without a definitive diagnosis.
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The term indeterminate colitis (IC) should be restricted to
cases where complete histologic analysis on the basis of
surgical specimens is possible.
3. Ulcerative colitis
3.1. Macroscopic diagnostic features
ECCO-ESP statement 8
Classically, macroscopic examination of a resection
specimen may show a continuous inflammatory pro-
cess, beginning from the rectum and extending proxi-
mally. Awareness of unusual macroscopic distribution
patterns, such as the cecal patch, rectal sparing and
backwash ileitis is important to avoid wrong subtyping
of the inflammatory bowel disease [EL3]
Gross examination of a resection specimen in UC classically
shows a diffuse and continuous chronic inflammation without
skip-areas which involves the rectum and spreads proximally
with gradually decreasing severity of inflammation. The
transition between the involved and the normal mucosa is
sharp in UC (Table 1). The mucosa has a friable granular
appearance and shows superficial ulcers. In severe disease
these ulcers may undermine the adjacent mucosa, finally
resulting in denudation of the mucosal surface or penetration
deep through the muscularis mucosae (well-like ulcers).34,35
Extensive ulceration with sparing of remainingmucosal islands
may give rise to inflammatory pseudopolyps which are
common in the sigmoid and descending colon, but rare in the
rectum. In fulminant colitis, the macroscopic appearance of
the mucosa is not sufficiently distinct to differentiate UC from
CD7,36 and serositis may be observed.37
Unusual inflammation patterns are rectal sparing, cecal
patch and backwash-ileitis. Rectal sparing may occur in
untreated children (30%), adults with fulminant colitis (13%) or
patients receiving topical or systemic treatment (44%).36,38–41
Another therapy-related finding is patchiness, i.e. a change
from continuous to discontinuous inflammation.40,41 The
association of left-sided colitis with inflammation surrounding
the appendiceal orifice is called ‘cecal patch’. Discontinuous
periappendiceal inflammation has been diagnosed in up to 75%
of patients with distal disease.27,42,43 “Backwash ileitis”
occurs in approximately 20% of patients with extensive colitis
or as a primary ileal mucosal inflammation without cecal
involvement.44 Distinction from Crohn's terminal ileitis can be
difficult.45,46 In longstanding UC, tissue repair is associated
with fibrosis, which, in contrast to CD, is commonly restricted
to mucosa or submucosa. This fibrosis may cause strictures in
3.2% to 11.2% of cases.47 In the quiescent phase of the disease
mucosal haustration will disappear resulting in an atrophic,
smooth mucosa.
3.2. Microscopic diagnostic features
ECCO-ESP statement 9
Microscopic diagnosis of ulcerative colitis is based on
widespread crypt architectural distortion, a diffuse
transmucosal inflammatory infiltrate with basal plas-
macytosis, eventually associated with an active com-
ponent, causing cryptitis and crypt abscesses. Mucin
depletion is less specific, but a helpful diagnostic
feature [EL 1]
UC is a chronic process with distorted architecture and an
inflammatory infiltrate which is limited to the mucosa.
Distorted crypt architecture (57–100%) with crypt branching
and atrophy and an irregular villous architecture (17–30%)
are more frequent than in CD (27–71% vs. 12%).15,48–50 The
disease is characterized by a lack of fissures.20 In fulminant
colitis ulcers may penetrate into the muscularis propria
Table 1 Macroscopic features used for the diagnosis of IBD.
Ulcerative colitis Crohn's disease
Localization GI tract Especially colon and rectum Whole GI tract
Ileum Not except in backwash-ileitis Often involved
Colon Left N right Right N left
Rectum Commonly involved Typically spared
Distribution GI tract Diffuse (continuous) Segmental (discontinuous)
Ulcers Superficial ulcers Aphtoid ulcers, confluent deep linear ulcers
Pseudopolyps Common Uncommon
Skip-lesions Absent Present
Cobblestone-pattern Absent Present
Deep fissures Absent except in fulminant colitis Present
Fistulae Absent except in fulminant colitis Present
Mucosal atrophy Marked Minimal
Thickness of the wall Normal Increased
Fat wrapping Absent Present
Strictures Uncommon Present
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(20%).51 The inflammatory infiltrate is diffuse or continuous
without any variations in intensity or skip-lesions and its
severity increases characteristically towards the rectum.
The mucosal inflammation is proportionate, i.e. the cellu-
larity is higher in the mucosa than in the submucosa.24,52
Occasionally, the inflammation may spread into the super-
ficial part of the submucosa. The inflammatory infiltrate is
composed of lymphocytes, plasma cells and neutrophils,
causing cryptitis, defined as the presence of neutrophils
within crypt epithelium, and crypt abscesses, defined as
the presence of neutrophils within crypt lumina (Table 2).
Crypt abscesses are more common in UC (41%) than in CD
(19%).48
Plasma cells are predominantly observed between the
base of the crypts and the muscularis mucosae (basal
plasmacytosis). This feature is helpful in the differentiation
between a first attack of UC (63%) and infectious colitis (6%),
but not CD (62%).15,49 The number of eosinophils is variable.
Based on three features, namely an increase of lymphocytes
and plasma cells in the lamina propria (including basal
plasmacytosis), the presence of crypt branching and
cryptitis, chronic inflammatory bowel disease (CIBD) can be
distinguished from non-CIBD.15 The inflammation may cause
mucin depletion of the epithelium, a less diagnostic feature
as it can also be found in infectious colitis and CD.13,49,53
Depending on the degree of inflammatory activity the sur-
face may become eroded. Features of chronicity also include
Paneth cell metaplasia (especially in left-sided colitis),
presence of inflammatory pseudopolyps, hypertrophy of the
muscularis mucosae and the rarely identified submucosal
fibrosis.54 Granulomas are not found in biopsies of patients
with UC, except those that are related to foreign bodies,
ruptured crypts andmucin extravasates.55 Le Berre et al. have
shown that a villous or irregular architecture, distorted crypt
architecture with crypt atrophy, mucin depletion and cryptitis
are features highly predictive of UC.56 Nevertheless, the
morphologic features may change attributable to disease
duration, patient age and treatment.
ECCO-ESP statement 10
Basal plasmacytosis is the earliest diagnostic feature
with the highest predictive value for the diagnosis of
ulcerative colitis [EL3]. Preserved crypt architecture
and the absence of a transmucosal inflammatory cell
infiltrate do not rule out ulcerative colitis at an early
stage. Therefore, repeat biopsies are recommended
not sooner than 6 weeks after the initial assessment
for the diagnosis of ulcerative colitis [EL3]
Improvement of endoscopic techniques has changed the
diagnostic approach to IBD with sampling of biopsies earlier
in the disease course before any treatment is initiated. In
early stage disease reliable diagnostic featuresmay be absent,
hampering diagnosis and distinction from CD and infectious
colitis, the latter being characterized by preserved crypt
architecture and acute inflammation.57 These histologic
features are however not diagnostic, as approximately 30%
of patients with a similar histologic pattern will progress
towards chronic CIBD.58 Surawicz et al. have shown that
infectious colitis lacks specific histologic features and is
diagnosed by exclusion of histologic features favoring IBD.12
The strongest predictor of IBD is basal plasmacytosis.59
Microscopic features more common in UC are crypt atrophy,
villous mucosal surface, superficial erosions and infiltration of
the surface epithelium with neutrophils, whereas epithelioid
granulomas are diagnostic for CD.12 Not all these microscopic
features are present in early stage disease, as only about 20%
Table 2 Microscopic features used for the diagnosis of IBD.
Ulcerative colitis Crohn's disease
Crypt architectural irregularity Diffuse (continuous) Focal (discontinuous)
Chronic inflammation Diffuse(continuous)
Decrease proximally
Focal (discontinuous)
Variable
Patchiness Uncommon Common
Localization Superficial
Transmucosal
Sometimes in submucosa
Transmural
Serositis Absent except in fulminant colitis Present
Lymphoid aggregates Frequent in mucosa, submucosa Common, transmural
Granulomas Absent, except with ruptured crypts Present
Acute inflammation Diffuse (continuous) Focal (discontinuous)
Crypt epithelial polymorphs Diffuse (continuous) Focal (discontinuous)
Crypt abscesses Common Uncommon
Mucin depletion Present, pronounced Uncommon, mild
Neuronal hyperplasia Rare Common
Muscular hypertrophy Absent Present
Paneth cell metaplasia Present Uncommon
Pyloric gland metaplasia Rare Present
832 F. Magro et al.
of the patients show crypt distortion within two weeks after
the first symptoms of colitis. Of note, basal plasmacytosis is
the earliest feature favoring IBD and can be observed in 38% of
the patients within two weeks after initial presentation.
During this period the distribution pattern of basal
plasmacytosis is focal but may eventually change into a
diffuse pattern during the disease course.59 This finding is in
contrast to the study by Nostrant et al., in which all UC
patients show basal plasmacytosis in the biopsies obtained
during the first attack of disease.57
ECCO-ESP statement 11
The diagnosis of long-standing disease is based on the
widespread crypt architectural distortion and the
presence of a diffuse increased transmucosal inflam-
matory cell infiltrate [EL 1]. In this situation themucosal
histology can be associatedwith someatypical features
such as normal mucosa, discontinuous inflammation
and rectal sparing. Awareness of these morphologic
features is important to avoidmisdiagnosis, in particular
change of diagnosis to Crohn's disease [EL3]
In long-standing disease the extent of gut involvement
decreases with time, ultimately leading to complete restora-
tion of the rectal mucosa (rectal sparing) in 34%–44% of
patients. In parallel, the distribution pattern changes mainly
from diffuse to non-diffuse or discontinuous (93%). 24,41 A
disturbed crypt architecture (78%) is more common than
an irregular mucosal villous architecture (33%), a decrease
in crypt number (44%) with mucosal atrophy (44%), or a
preserved architecture (22%).59 Restoration of the architec-
ture may result in a normal mucosa.24 The presence of normal
crypt architecture may cause a diagnostic dilemma during
follow-up. Although basal plasmacytosis is still the most
important feature with the highest prevalence, it is not a
distinctive feature, as it is as common in UC (63%) as in CD
(62%).15,59 Other diagnostic features favoring UC are an
increase in transmucosal cellularity, cryptitis, crypt abscess-
es, mucin depletion and Paneth-cell metaplasia.52,60 Long-
standing UC can be associated with (endoscopic and histolog-
ic) patchiness (38%).41
ECCO-ESP statement 12
In quiescent disease, the mucosa in ulcerative colitis
may showsome features related to architectural damage
and recovery, such as architectural crypt distortion
(atrophy and branching) as well as epithelial regenera-
tion, disappearance of basal plasmacytosis and in-
creased transmucosal cellularity. Active inflammation
is usually not observed [EL3]
Remission is defined as complete resolution of symptoms
and endoscopic mucosal healing.1 Histologically, mucosal
healing is characterized by resolution of the crypt architec-
tural distortion and the inflammatory infiltrate.59 However,
the mucosa will still show some features of sustained damage,
such as a decreased crypt density with branching and shorten-
ing of the crypts.61,62 In addition, reduced epithelial regener-
ation will usually reduce mucin depletion, i.e. restore the
mucin content of epithelial cells.63 The cellularity and the
composition of the inflammatory cell infiltrate are variable
and either a hypercellular lamina propria with presence of
chronic inflammatory cells or a hypocellular lamina propria
with reduced number of mononuclear cells and resolution
of neutrophils can be observed. Ultimately, basal plasma-
cytosis decreases, resulting in normal cellularity. In contrast
to neutrophils, the number of eosinophils does not change in
this phase.64 Persistence of the lamina propria cellularity
with basal plasmacytosis or a high number of eosinophils is
associated with a substantial risk of relapse.59,65,66 Histolog-
ical features predictive of ensuing relapse also include acute
inflammatory cell infiltrate, crypt abscesses, mucin depletion
and surface epithelium damage.67 Remission may result as a
complete normalization of the mucosa in approximately 24%
of cases which, without clinical information, may hamper the
diagnosis of UC.68,69
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Treatmentmay change the classical distribution pattern
of the inflammation. Patchiness, rectal sparing up to
normalization of the mucosa can be observed. Aware-
ness of these treatment-related effects is important in
the evaluation of biopsies from treated patients to avoid
misdiagnosis [EL3]. The pathology report should give
an indication of the activity of the disease [EL5]
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Histologic findings predictive of ensuing clinical relapse
in patients with quiescent ulcerative colitis are basal
plasmacytosis, increased transmucosal cellularity, high
number of neutrophils and eosinophils, crypt abscesses,
mucin depletion and damage of the surface epithelium
[EL4]
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Testing for CMV reactivation on colonic biopsy should
be performed in all patientswith severe colitis refractory
to immunosuppressive therapy. In addition, testing
should be performed in biopsies with prominent granu-
lation tissue derived from large ulcers [EL2]. Semiquan-
titative immunohistochemistry, reporting the number of
infected cells and/or the number of CMVpositive biopsy
fragments, may have a predictive value. Testing in other
groups should be on a case by case basis [EL5]
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Treatment may induce complete restoration of the
architectural distortion with decrease of the intensity of
inflammation.70 The classical distribution pattern of the
inflammation may change from diffuse or continuous to
patchy or discontinuous. Discontinuity and patchiness are
both features characteristic for CD. Lacking information on
foregone treatment the accuracy of the initial diagnosis of
UC may be questioned in these cases.71 In clinical trials
therapeutic outcomes are measured by various indices that
evaluate disease activity based on clinical, hematological
and endoscopic parameters.72 Histologically, the level of
activity and the stage of the disease (e.g. flaring vs.
quiescent UC) can be assessed by different scoring sys-
tems.34,73,74 Although these are not applied routinely, the
pathology report should include some information on the
level of activity in the biopsies in order to assess both the
effect of therapy and the risk of relapse.
In patients with UC the risk for reactivation of a latent
cytomegalovirus (CMV) infection is increased and is signif-
icantly higher than in CD (10%–56.7% vs. 0%–29.6%).75
Reactivated CMV infection increases the severity of disease
and is associated with higher rates of morbidity and
hospitalization.76,77 The risk of CMV reactivation depends
on the type of immunosuppressive drugs used and is higher in
steroid-refractory than in steroid-responding patients (25–
30% vs. 0–9.5%).75,78 CMV reactivation should be routinely
sought for in case of flares or unresponsiveness to treat-
ment. Although CMV viral inclusions may be detected on
H&E-stained slides, immunohistochemistry or molecular tech-
niques such as quantitative PCR, aremore sensitive techniques
with a high diagnostic accuracy.75
3.3. Children and adolescents
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In comparison with adults, a higher proportion of
children with UC presents initially with subtotal or with
extensive colitis [EL2]. As in adults, the presence of
“backwash ileitis” does not exclude a diagnosis of
UC. The prevalence of backwash ileitis seems to be
similar in children and adults [EL3]. Periappendiceal
inflammation, without more extensive and significant
cecal inflammation, is frequently seen in UC. Such
inflammation should not be regarded as supportive
evidence for the diagnosis of CD [EL 3]. In young
children with aberrant presentation of disease, ulcera-
tive colitis should always be considered in the
differential diagnosis even if histology is not typical
[EL1]
IBD is an important cause of gastrointestinal pathology
in children and adolescents. About 10–15% of patients
are diagnosed before the age of 18 years.79 Given the
serious consequences of IBD on growth and development,
early and accurate diagnosis of pediatric patients is essential.
Pediatric-onset IBD is characterized by distinct phenotypic
differences compared to adult-onset IBD. This finding may
hamper the diagnosis, resulting in delayed or inadequate
therapy. The gold standard for diagnosing pediatric IBD
remains endoscopic evaluation of the upper and lower
gastrointestinal tracts, with mucosal biopsies for histopatho-
logic confirmation.80–82 In a series of 62 children 21 (34%) had
colitis limited to the rectum or rectosigmoid, 24% left-sided
colitis, and in 42% extensive colitis was diagnosed. In another
study, left-sided colitis was seen at diagnosis in 10% of
60 children with UC, whereas extensive colitis occurred in
90%.79
Untreated children most commonly present with an ex-
tensive colitis with less severe and less diffuse architectural
abnormalities.38,39,79,80,83 Backwash ileitis in children is as
common as in adults. In a series of 18 children newly
presenting with UC, 39% showed erythema with no erosions
or ulcers and associated histologic nonspecific inflamma-
tion.84 Regarding appendiceal involvement, only one pediatric
study examined appendices from resected intestinal speci-
mens in 17 UC and 24 CD patients who failed to medical
therapy. All children had appendiceal involvement.85 The
clinical significance of such inflammation remains unclear. In
children under 10 years of age, the colonic mucosa may show
less architectural distortion and inflammation than adoles-
cents or adults. Although basal plasmocytosis is less common
in children (58%) than in adults (38–100%), it is an early
feature in young children.39,83 Untreated children with UC
may present with a normal mucosa or mild patchy inflamma-
tion at disease onset or with an unusual inflammation pattern,
such as patchiness (21%) and rectal sparing (30%).38,39,86
Relative rectal sparing ismost commonly diagnosed in children
less than 10 years of age.83 When children approach adult-
hood, the histologic features are similar to that found in
adults.87 Upper gastro-intestinal inflammation is not diagnos-
tic for CD, as esophagitis, minimal to mild non-specific
gastritis or focally enhanced gastritis may be present in up to
75% of children with UC.88–90 Although Helicobacter
pylori-negative focally enhanced gastritis is more common in
children with CD (43–76%) this is also seen in UC patients (8–
21%).90–92 Granulomas, however, are only found in CD.93
Duodenitis is also not uncommon in children with UC (22–
27%).88,93
3.4. Colorectal cancer
The incidence of colorectal cancer (CRC) in UC is approxi-
mately 4/1000 per person year of disease, with an average
prevalence of 3.5%.94 Colorectal cancer risk is associated with
disease duration and disease extent95–98 and raises at a rate of
approximately 0.5 to 1% per year after a total duration of
colitis of 8 to 10 years.99–101 The highest cancer risk is ob-
served in extensive colitis, whereas no or only moderate risk is
found in ulcerative proctitis or left-sided disease.95,97,98
Additional risk factors include primary sclerosing cholangitis
(PSC), early age of onset of colitis, severity of microscopic
inflammation, the presence of pseudopolyps and a family
history of CRC.96,99,102–106
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Dysplasia (intrepithelial neoplasia) represents the best
and most reliable marker of malignancy risk in patients
with ulcerative colitis. Colitis-associated dysplasia de-
velops only in areas with chronic inflammation and can
be divided into 4 morphologic categories: negative
(regenerating epithelium), indefinite and positive for
low-grade dysplasia and high-grade dysplasia [EL 2].
Inter-observer agreement is poor for low-grade and
indefinite dysplasia. Confirmation of dysplasia by an
independent expert GI pathologist is recommended
[EL 2]
Dysplasia is defined as histologically unequivocal neo-
plastic epithelium without evidence of tissue invasion.107
Dysplasia is the best and most reliable marker of an in-
creased risk of malignancy in patients with UC.98,108,109 For
diagnostic reasons, dysplasia is separated into three distinct
categories: negative for dysplasia, indefinite for dysplasia
(“questionable” dysplasia) and positive for dysplasia108
(low or high grade). In 2000, the “Vienna classification” was
introduced as an alternative system to grade dysplasia, and
the following four categories were proposed: category 1,
non-dysplastic mucosa; category 2, lesions which are indef-
inite for dysplasia; category 3, genuine dysplasia correspond-
ing to non-invasive low-grade neoplasia and category 4,
genuine dysplasia corresponding to non-invasive high-grade
neoplasia.110 Thus, this classification proposed the term
“non-invasive neoplasia” instead of dysplasia.110
Dysplasia may occur in any part of the colon and is most
oftenmultifocal, presenting as isolated foci. Dysplasia related
to IBD develops only in areas with chronic inflammation.98,109
The microscopic features that are used for diagnosis of
dysplasia are analogous to those characterizing neoplastic
growth in general, including both architectural and cytological
abnormalities. Architectural abnormalities are crowding of
glands, thickening of the mucosa and lengthening and
distortion of the crypts with excessive budding and increased
size. Surface and crypts are lined by tall, high columnar cells in
which there is some mucus differentiation. Mucin tends to be
in columnar cells rather than in the usual goblet cells. Nuclear
changes are morphologically similar to those seen in tubular
adenomas in non-IBD patients: hyperchromatic and enlarged
nuclei, with nuclear crowding and frequent overlapping. The
nuclei are also typically stratified. Mitotic figures may be
present in the upper part of the crypts and even in the surface
(which is abnormal).108
A fair inter-observer agreement is noted for high-grade
non-invasive neoplasia (dysplasia) and samples negative
for dysplasia; however, even experienced gastrointestinal
pathologists show a poor inter-observer agreement for low-
grade and indefinite dysplasia. Therefore current practice
emphasizes the need for a second opinion from another
expert pathologist.98,111–117
Recent studies have focused on adjunctive methods to
improve inter-observer variability in detecting dysplasia.
P53 tumor suppressor gene appears as a key factor in the
initial steps of IBD-associated colorectal carcinogenesis
being the most frequent single founding mutation in UC-
associated CRC.118 P53 is overexpressed in 33–67% of
patients with dysplasia and in 83–95% of patients with
UC-associated CRC119,120; however, a small proportion of
regenerating, non-dysplastic cases may also be positive.
Therefore, p53 immunostaining is fraught with a consider-
able false-positive rate which makes p53 less useful for
differentiating regeneration from true dysplasia. Alpha
methyl-CoA racemase has been shown to be sensitive and
highly specific for dysplasia in IBD with an increase in
positivity in low grade dysplasia and adenocarcinoma.121,122
Clinical follow-up data obtained from indefinite and low-
grade dysplasia with p53/AMACR co-expression show an early
progression to high-grade dysplasia and cancer.123 Recently
it was shown that 86% of patients with co-expression of p53
and AMACR developed advanced neoplasia compared to 27%
without co-expression.121
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Colitis-associated dysplasia consists of flat and
elevated lesions. Elevated lesions request sampling
of the surrounding and remote mucosa for diagnosis
and treatment decision [EL 2]
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For surveillance 4 biopsy specimens should be taken
from every 10 cm of the entire colon in addition to
biopsies from macroscopically visible atypical lesions
[EL 2]
There are two gross patterns of dysplasia in UC: flat and
elevated lesions. Flat dysplasia is defined as a lesion the
thickness of which is less than two times that of normal
mucosa.124 It is a common lesion, not endoscopically visible,
which carries a high risk for CRC.94 Flat lesions are detected
microscopically in randombiopsies fromunremarkablemucosa.
To diminish the risk of sampling error current practice
guidelines recommend that 4-quadrant biopsy specimens
should be taken from every 10 cm of the entire colon in
addition to biopsies from macroscopically visible atypical
lesions.96,125,126 Emerging endoscopic techniques, namely
chromoendoscopy, high-resolution magnification endoscopy,
confocal laser endomicroscopy and endocytoscopy promise to
increase the yield of surveillance colonoscopy by identifying
subtle lesions that would be missed by white-light endoscopy
and decrease the work load of the pathologists.127–129
Compared to conventional endoscopy with random biopsies,
targeted biopsies guided by magnifying chromoendoscopy are
of superior sensitivity in detecting flat dysplasia in longstanding
UC.130–134 Chromoendoscopy is increasingly being incorporated
in practice guidelines of several Societies but the key point is to
prove an increase in detection rates of dysplasia. Limitations
are the time-length of the procedure, unequal staining, cost
and potential genotoxicity of absorbed dyes.
Raised or elevated dysplastic lesions are a heterogeneous
group including adenoma-like lesions and non-adenoma-like
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lesions.135–137 Non-adenoma-like lesions can either appear
as large velvety patches, irregular plaques, irregular bumps
and nodules, wart-like lesions, large sessile polypoid lesions
with a broad base or even as localized strictures.135,137,138
Adenoma-like lesions are usually well-circumscribed small
lesions, with sometimes a sessile configuration similar to
those of sporadic adenomas unrelated to UC. Several clinical
andmicroscopic features have been identified which may help
to differentiate colitis-associated dysplasia from adenoma-like
lesions32,137,139,140 These may also be referred to in patients
with CD disease and they are summarized in Table 3. On
microscopic examination, non-adenoma-like elevated lesions
are more heterogeneous and have a tubulo-villous appear-
ance, with sometimes a mixture of neoplastic glands and
normal crypts with intense inflammation. In this situation the
flat mucosa surrounding the raised lesion may show dyspla-
sia.137 Thus, it is crucial to obtain samples of the surrounding
non-elevated mucosa.
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Adenoma-like lesions (sporadic adenomas) may be
difficult to distinguish from colitis-associated dysplasia.
The distinction is however important, because the man-
agement of sporadic adenomas differs from that of
colitis-associated dysplasia. The patient's age, the site
and morphology (endoscopic appearance, microscopy)
of the lesion, along with biopsies of flat surrounding
mucosa, may be helpful in this distinction [EL2]
Flat high-grade dysplasia is frequently associated with
CRC.98 At the time flat high-grade dysplasia is diagnosed CRC
may already be present in 42 to 67% of cases.96,101 The risk of
flat low-grade dysplasia is controversial in the literature
with a poor consensus regarding the optimal management
strategy.141–144 A recent meta-analysis concluded that the
positive predictive value for CRC in patients with flat
low-grade dysplasia is 22%. Patients with low-grade dysplasia
carry a 9-fold higher risk for CRC than patients without
dysplasia. If patients with low-grade dysplasia are treated
without surgery, the subsequent 5-year rate of progression
to either high-grade dysplasia or CRC ranges from 23% to 54%
but a report from Karolinska showed that none of the
patients progressed to HGD or CRC during a mean follow-up
of 10 (range 1–22) years.101,116,138,141,144 Current evidence is
insufficient to assess the balance of risks and benefits of
colectomy for flat low-grade dysplasia. Thus, the decision to
undergo colectomy versus continued surveillance in patients
with flat low-grade dysplasia should be individualized and
discussed at length with the patient.96,145 The progression of
colorectal neoplastic lesions in patients with long-standing
UC varies in function of the colonic location. A pooled
analysis by Choi demonstrated a distal predominance for
UC-associated CRCs.117,146 In addition, distal low-grade
dysplasia progresses more rapidly to cancer than proximal
low-grade dysplasia.145 Consequently, it is recommended
that more biopsies should be taken from the rectosigmoid
area during follow-up colonoscopy.96
Recent data suggest that polypectomymay be an adequate
treatment for patients with an adenoma-like dysplastic
lesion.109,135,140,147–149 If a polypectomy is performed, a
complete excision of the lesion is necessary. Vieth et al.
have shown a high rate of progression to cancer in patients
with incompletely removed raised adenoma-like dysplasia.140
By contrast, colitis-associated polypoid dysplasia has a high
risk of concurrentmalignancy and should thus be considered as
an indication for colectomy or proctocolectomy.138,150
3.5. Special situation
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For a proper histologic evaluation of pouchitis multiple
biopsies are recommended. The exact location has not
been determined but according to some data it is useful
to take biopsies from the anterior and posterior wall
avoiding suture lines. Samples from the posterior wall
are more likely to show the inflammatory changes [EL 2]
Proctocolectomy with ileal pouch anal anastomosis (IPAA)
has replaced the Kock's pouch as the procedure of choice for
most patients with UC requiring colectomy. “Pouchitis” refers
now to active inflammation of IPAA mucosa and is considered
as a primary “non-specific, idiopathic inflammation of the
neorectal ileal mucosa”.151,152 The incidence of pouchitis
ranges between 10 and 59% depending on the diagnostic
criteria used, the accuracy of evaluation and possibly the time
interval since the IPAA operation. Risk factors include
extensive colitis, primary sclerosing cholangitis,
non-smoking, detection of p-ANCA and the use of
Table 3 Microscopic and clinical features used for the
differential diagnosis of neoplastic lesions in inflammatory
bowel disease.
Colitis-associated dysplasia
Age b 50 years
Extent of disease: usually total
Usually active disease
Longer disease duration (N10 years)
Associated flat dysplasia common (no sharp delineation)
Irregular neoplastic glands (varying configuration, size and
diameter) with varying amounts of stroma
Increased (mononuclear) lamina propria inflammation common
Mixture of benign/dysplastic crypts at surface common
Adenoma-like lesion (sporadic adenoma)
Age N 60 years
Extent of disease: usually subtotal
Usually inactive disease
Shorter disease duration (b10 years)
No associated flat dysplasia (sharp delineation)
Regular neoplastic glands (similar configuration, size and
diameter) with low amounts of stroma
Increased (mononuclear) lamina propria inflammation
uncommon
Mixture of benign/dysplastic crypts at surface rare
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non-steroidal anti- inflammatory drugs (NSAIDs). Interesting-
ly, only a small minority of IPAA patients operated for
adenomatous polyposis coli develop pouchitis.
Three to 20% of patients develop persistent or recurrent
episodes of pouchitis.153 Some patients may develop CD-like
complications including perianal fistulas and inflammation,
stenoses or fistulas in the pre-pouch ileum and/or the pouch.
The diagnosis of pouchitis is based on a combination of
clinical symptoms, endoscopic and histologic findings.
Diagnosis based on symptoms alone is accurate in only 55%
of the patients. There is a good correlation between more
severe grades of histological inflammation, frequency of
defecation and endoscopic appearance. Histologic changes
may be patchily distributed but are more prominent in the
lower and posterior regions of the pouch. Consequently,
multiple biopsies from these sites are essential for the
diagnosis.154 Various scoring systems have been developed
to standardize the diagnosis and assess the severity of
pouchitis. The Pouchitis Disease Activity Index (PDAI) calcu-
lates symptoms, endoscopy and histology on three separate
6-point scores; a total score higher than 7 is indicative of
pouchitis.155,156 Pouchitis should be distinguished from
“cuffitis” or “short-strip pouchitis”, which is inflammation in
the columnar cuff mucosa distal to the pouch. The top end of
the anal canal is lined by columnar mucosa like that of the
rectum. In a hand sewn IPAA, this mucosa is stripped, albeit
often incompletely since the junction between columnar
epithelium and squamous or transitional epithelium is difficult
to distinguish. Islands of columnar mucosa may be left behind.
This is also true in a double stapled pouch anastomosis
although the amount of columnar mucosa varies widely. In
these patients symptomsmay be due to an exacerbation of UC.
Chronic inflammatory changes, present in up to 87% of
biopsies from ‘healthy’ pouches, consist of architectural
distortion, villous atrophy, crypt hyperplasia and infiltration
of the lamina propria by mononuclear cells, eosinophils and
histiocytes. Neutrophils are rarely present. Villous atrophy
and crypt hyperplasia are considered to be adaptive changes
(“colonic metaplasia”). The concept of “colonic phenotype”
is supported by experimental data showing that human
tropomyosin isoform 5 (hTM5) is expressed diffusely in the
goblet cells and non-goblet cells lining the crypts and the
lumen in the ileal pouch of UC patients 6 months post IPAA
surgery, but is not expressed or is focally expressed only in
goblet cells in genuine ileal samples. These changes were
associated with shortening and reduced number of the
villi.157 Adaptive changes have been classified into three
patterns: a healthy villous mucosa, a mucosa which remains
flat and chronically inflamed and a mucosa with intermittent
inflammation and architectural recovery. Mild ischemic
changes can be observed in a few patients, while others may
show features of mucosal prolapse, such as fibromuscular
obliteration of the lamina propria and a disrupted muscularis
mucosae. Features of prolapse are most commonly seen in
samples from the anterior wall. In contrast, in pouchitis
patchy intraepithelial neutrophils becomemore numerous and
induce cryptitis, crypt abscesses and ulcerations. As “colonic
metaplasia” occurs more frequently in cases with pouchitis, it
has been suggested that it may be a “reparative” rather than
an “adaptive” response.158
The histology of chronic refractory pouchitis is mostly
identical to that of “usual” pouchitis. In this situation other
possible causes such as infections (particularly CMV) should
be considered. The development of CD-like complications in
chronic pouchitis may cast doubt on the initial diagnosis.
Biopsy specimens usually show features of severe inflamma-
tion with neutrophils within the lamina propria and
epithelium, erosions, ulcerations and mucosal architecture
distortion. Histology of excised pouches for these complica-
tions may show deep submucosal lymphoid aggregates and
granulation tissue-lined fistulous tracts. Similar changes, and
even granulomas, have been observed in defunctioning rectal
stumps left in situ after urgent total colectomy for UC.159 The
occurrence of CD-like complications and the presence of
deeply situated lymphoid aggregates should not refute the
diagnosis of UC. A diagnosis of CD after IPAA surgery should
only be made when re-examination of the original
proctocolectomy specimens shows typical pathologic features
of CD.160 Pyloric gland metaplasia reflects chronicity of the
process. Trauma, prolapse, NSAID-induced injury and CD must
be considered.161
Diffuse mucosal active and chronic inflammation with
villous and crypt distortion and ulceration can be observed in
samples from the ileum above the pouch. This may occur in
patients with pouchitis or without inflammation in the pouch.
The lesions can be related to pouch outlet obstruction or to
obstruction at the ileal-pouch anastomosis. They are not
self-evident for a possible diagnosis of CD. The occurrence of
ulcers in the afferent limb may predict CD. They can also
rarely be observed in patients with IPAA taking NSAIDs.162
4. Crohn's disease
4.1. Macroscopic diagnostic features
CD may affect any part of the gastrointestinal tract form the
mouth to the anus. Most commonly, the disease affects the
terminal ileum, often in association with the right colon.
Large bowel involvement by CD may be found in isolation (in
approximately 20% of cases, with preferential right-sided
localization) or may co-exist with CD at other sites.163 Crohn's
colitis and its distinction from UC was first characterized
by Lockhart–Mummery and Morson.164 Warren refers to
three basic pattern of large bowel involvement: CD isolated
to the rectum, stricturing large bowel CD and diffuse
Crohn's colitis which typically occurs with (relative) rectal
sparing.163 Approximately 75% of patients with large bowel
CD develop perianal pathology, including skin tags, deep
ulcers, fissures, fistulae, abscesses, blind sinus tracts and
strictures at some point during the disease course.163 Of
note, perianal CD may predate intestinal involvement by
years.
Classically, the gross examination of a resection specimen
in CD shows a discontinuous pattern of inflammation. Diseased
segments are frequently separated by areas of uninvolved,
i.e. normal bowel (“skip lesions”). Transition from involved to
uninvolved areas is usually abrupt. The surface of the involved
bowel segment may appear hyperemic. An inflammatory
serosal exudate and/or serosal adhesions may be observed.
Mainly in small bowel CD, but infrequently also in large bowel
CD “fat wrapping” is seen which is characterized by adipose
tissue expanding towards the antimesenteric surface. Fat
wrapping has a high predictive value for the diagnosis of CD,165
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but it has also been observed, together with other Crohn's
colitis-like changes (fissuring ulcers, granulomas, transmural
lymphoid aggregates) in individuals with segmental colitis
associated with diverticulosis (SCAD).166,167 SCAD is defined as
a chronic inflammatory process confined to a diverticular
segment and does therefore almost exclusively affect the
sigmoid colon. By definition, both the rectum and the proximal
colon are endoscopically and histologically normal.168,169
The pathogenesis of the disease is unclear. An idiosyncratic
inflammatory response to diverticular disease has been
discussed.167
The earliest grossly visible mucosal lesions of CD are small
aphthous ulcers that typically develop over lymphoid follicles.
Of note, the adjacent mucosa is quite normal on gross
inspection. As the aphthous ulcers enlarge, they coalesce to
large deep serpinginous or linear ulcers with overhanging
oedematous mucosal edges. Islands of oedematous, non-
ulcerated mucosa, separated by deep discrete ulcers may
give rise to the classic cobblestone appearance. Inflammatory
polyps and pseudopolyps may occur, the latter reflecting
residual mucosa islands interspersed between area of ulcer-
ation. Healed ulcers leave scars that are typically depressed.
Fistulae are a common finding in small bowel CD. Though
being relatively rare, theymay be observed also in colonic CD,
mainly in patients with ileal involvement and/or ileocolitis.
Free perforation, however, is exceptional in colonic CD.
Strictures may develop at sites of transmural inflammation
with fibrosis and fibromuscular proliferation. As in the small
bowel, the bowel wall may become thickened and increasingly
rigid. Finally, it has to be acknowledged that in surgical
specimens the macroscopic aspects and the transmural
character of the disease as well as fistulae can be identified
and, in general,manymore features can be used for diagnostic
purposes, particularly in the differentiation of CD from UC
(Table 1).20,21
4.2. Microscopic diagnostic features
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Focal (discontinuous) chronic inflammation, focal crypt
irregularity (discontinuous crypt distortion) and granu-
lomas (not related to crypt injury) are the generally
accepted microscopic features which allow a diagnosis
of CD in the colon (on endoscopic biopsies) [EL2]. The
same features and, in addition, an irregular villous
architecture, can be used for analysis of endoscopic
biopsy samples from the ileum. If the ileitis is in
continuity with colitis, the diagnostic value of this
feature should be used with caution [EL2]
A large variety of microscopic features have been identi-
fied which help to establish a diagnosis of CD (Table 2). The
reproducibility of these features aswell as their sensitivity and
specificity has been studied repeatedly.
Focal (discontinuous) chronic inflammation means a vari-
able increase in lamina propria cellularity (lymphocytes and
plasma cells) across the biopsy specimen and not confined to
the superficial zone. Specifically, focal inflammation implies a
localized increase in round cells with or without granulocytic
infiltration, confined to one or more foci. These foci of
inflammation may occur against a normal round cell back-
ground or in biopsies with variable degrees of inflammation.
Normal lymphoid aggregates do not denote focal inflamma-
tion. Differences in cellularity between multiple biopsy
specimens can be assessed with greater reproducibility than
variation within a single specimen. There may be extension of
inflammation into the submucosa in a biopsy.
Crypt irregularity implies abnormalities in N10% of the
crypts. Crypt irregularity may be seen in biopsies with or
without inflammation. Crypt irregularity is characterized either
by crypt distortion (non-parallel crypts, variable diameter or
cystically dilated crypts), crypt branching and crypt shorten-
ing.48 The presence of more than two branched crypts in
a well-orientated biopsy specimen should be regarded as
abnormal.14,48
The granuloma in CD is defined as a collection of
epithelioid histiocytes (monocyte/macrophage cells), the
outlines of which are often vaguely defined. Multinucleated
giant cells are not characteristic and necrosis is usually not
apparent. Only granulomas in the lamina propria not
related to crypt injury may be regarded as a corroborating
feature of CD. Granulomas associated with crypt injury are
less reliable features.55 Noncaseating granulomas, small
collections of epithelioid histiocytes and giant cells, or
isolated giant cells can be observed in infectious
colitis (granulomas suggest Mycobacterium sp., Chlamydia
sp., Yersinia pseudotuberculosis and Treponema sp.;
microgranulomas suggest Salmonella sp. Campylobacter sp.
and Yersinia enterocolitica; and giant cells suggest Chlamydia
sp.) and must not be regarded as evidence for CD. In patients
living in or originating from areas with a high prevalence of
tuberculosis, intestinal tuberculosis should be actively ex-
cluded in patients with suspected CD. This is of particular
relevance before starting anti-TNF therapy.170
In resection specimens, transmural lymphoid aggregates
(transmural lymphoid hyperplasia), particularly away from
areas of ulceration, and granulomas not related to crypt
injury are typical discriminating features for a diagnosis of
CD as opposed to other conditions, particularly UC. In a study
on colectomy specimens operated upon for fulminant colitis,
granulomas and lymphoid aggregates proved to be the two
most specific indicators.36
Pyloric gland metaplasia, also referred to as
pseudopyloric gland metaplasia or glandular mucoid metapla-
sia, is a feature indicative of chronic mucosal inflammation,
commonly related to mucosal ulceration and repair (ulcer
associated cell lineage — UACL).171 The lesion can be observed
in 2–27% of ileal biopsies from patients with CD and is common
in ileal resections. However, the lesion is exceedingly rare in
resection specimens from patients with backwash-ileitis in UC,
having been described only in cases with active ileal
inflammation and/or ulceration.44
To the best of the authors' knowledge, pyloric gland
metaplasia has so far not been identified in ileal biopsies from
patients with ulcerative colitis, with or without backwash-
ileitis.9,45,46 Pyloric gland metaplasia has, however, been
observed in up to 40% of pouch biopsies of patients with UC
and restorative proctocolectomy with ileal pouch-anal anasto-
mosis. In this setting, pyloric gland metaplasia appears to be a
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specific marker for chronic antibiotic-refractory pouchitis or CD
of the pouch.161
The selection of the number of features needed for
diagnosis is based on a systematic literature review. They
achieve a diagnostic sensitivity and specificity of at least 50%
and a moderate to good reproducibility (kappa of 0.4 or
percentage agreement of at least 80%).15,50,172 They were
presented to a panel of experts and scored according to the
quality of the study and expert opinion. Focal crypt irregular-
ity scored highest on the evidence of more than one valid
study of adequate size and from expert opinion; focal or
patchy chronic inflammation was validated by evidence from
single paper and expert opinion. The features were also tested
in a workshop, involving non-expert and expert pathologists
and selected by 50% or more of the pathologists correctly
identifying each case.8 The patchy nature of the inflammation
is only diagnostic in untreated adult patients. Inflammation
can become patchy in resolution of active UC, and young
children (age b 10 years) with UC may present with discon-
tinuous inflammation.24,38,71,83,86,173
The presence of one single feature is not regarded as
sufficient for a reliable diagnosis of CD. For single or multiple
endoscopic samples there are no data available as to howmany
featuresmust be present for a firmdiagnosis of CD. For surgical
material, it has been suggested that a diagnosis of CD disease
should be made when three features are present in the
absence of granulomas, or when an epithelioid granuloma is
present with one other feature provided that specific in-
fections are excluded. The same definition could be applied to
endoscopic biopsies. The following features can be identified
in the mucosa and thus in biopsy samples: granulomas and
focal (segmental or discontinuous) crypt architectural abnor-
malities, in conjunction with focal chronic inflammation, or
mucin preservation at active sites. These are, therefore,
potentially reliable markers for the diagnosis of CD.
The majority of expert clinicians and all pathologists
agree that the presence of a granuloma and at least one
other feature establishes a diagnosis of CD. The second
feature can be either (focal) inflammation or, preferably,
architectural abnormalities. While focal architectural ab-
normalities favor CD, pseudovillous appearance of the
colorectal surface is more consistent with a diagnosis of
UC. The presence of a granuloma is not a prerequisite for
the diagnosis of CD. Additional features which have been
found to be useful are focal chronic inflammation without
crypt atrophy, focal cryptitis (although reproducibility is
poor),8,172,174 aphthoid ulcers, disproportionate submucosal
inflammation, neural hypertrophy (nerve fiber hyperpla-
sia),20,175 increased intraepithelial lymphocytes,8 and prox-
imal location of ulceration and architectural distortion.
When multiple biopsies are available, ileal involvement and
a distribution of the inflammation showing a proximal to
distal gradient can also be useful. The absence of features
that are highly suggestive or diagnostic of UC, such as diffuse
crypt irregularity, reduced crypt numbers and general crypt
epithelial polymorphs, can also orient towards a diagnosis of CD.
In difficult cases, esophageal, gastric and duodenal
biopsies might help to establish the diagnosis of CD by the
presence of granulomas or focally enhanced or focal active
inflammation. In gastric biopsies, the absence of (i.e.
Helicobacter pylori) and the presence of a perifoveolar or
periglandular cellular infiltrate composed of mononuclear
cells (CD3+ T cells and CD68+ histiocytes) and granulocytes
are important features. On the other hand, focal gastritis is
not exclusive to CD.92,176–179
ECCO-ESP statement 23
Despite detailed histologic criteria used to differentiate
Crohn's colitis from ulcerative colitis in colonoscopic
biopsies, accurate discrimination between the two dis-
eases is not yet optimal among expert gastrointestinal
pathologists [EL 2]
Colonoscopic biopsies are an essential step in the
diagnostic work-up of patients with IBD. Comprehensive
guidelines for reporting the diagnostic features have been
published.16,17,180–182 In contrast, few studies have analyzed
in detail the reliability and/or reproducibility of the histolog-
ical changes that distinguish IBD from other forms of colitis,
and CD disease from ulcerative colitis.52
Because no single pathognomonic lesion has been identified
to date for the most common forms of colitis, the diagnosis
usually derives from a complex evaluation of multiple micro-
scopic changes and their topographical distribution. The
results of an International Workshop on the initial histopath-
ologic diagnosis of colitis indicated that expert gastrointestinal
pathologists correctly identified 64% of cases with CD and
74% of cases with UC.8 These figures may be considered
discouraging, at least with regard to the individual patient.
Fiocca and Ceppa183 summarized the conclusions drawn by this
International Workshop of expert gastrointestinal pathologists
as follows: (i) Multiple colonoscopic biopsies are necessary
to provide an accurate diagnosis of CD, (ii) rectal biopsies
alone are not diagnostic, (iii) overall diagnostic accuracy of
endoscopic biopsies is lower in CD than in UC, (iv) discussion of
diagnostic criteria and guidelines among pathologists may
improve the diagnostic accuracy, especially in CD, (v) several
helpful diagnostic features that contribute to the diagnosis of
CD in surgical specimens, such as transmural inflammation,
fibrosis and fistulas are present only in the deep layers of the
bowel wall alone and therefore not accessible to endoscopic
biopsy sampling, (vi) in contrast, most lesions in UC are limited
to the mucosa and submucosa and consequently can be
properly assessed by endoscopic biopsies.
4.3. Children and adolescents
ECCO-ESP statement 24
At onset, CD in children is associated with more colitis
and less ileitis. The frequency of granulomas is higher in
children than in adults. Focal inflammation in the upper
gastrointestinal tract is of assistance in differentiating
CD from UC [EL 2]
A subgroup of pediatric patients may have a specific
disease phenotype that differs from adults. The primary
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difference is the topographical distribution and/or extent of
disease. Compared to adults, first-decade pediatric onset is
associated with more colitis and less ileitis.184 In children
with severe CD, all biopsies obtained during the same
colonoscopic investigation may show chronic inflammation
(with or without acute inflammation), including the rectal
mucosa, thus introducing diagnostic difficulties in differen-
tiating between CD and UC. In these cases, it is essential to
identify, in each one of the multiple colonic biopsies, areas
with inflammation alternating with areas with much less (or
without) inflammation, since focal distribution of on-going
inflammation is highly suggestive of CD.
A puzzling difference between CD in pediatric and adults
patients is that epithelioid-cell granulomas are more frequent
in children, particularly in the disease course. Thus, granulo-
mas at initial colonoscopy were recorded in 67% of children
and 66% of adults, but at subsequent colonoscopies in 54% of
children and only 18% of adults, suggesting that granulomas in
Crohn's colitis might evolve or regress at different time
intervals during the course of the disease.185 In another study
on children with CD undergoing esophagogastroduodenoscopy
and colonoscopy, granulomas were identified in 61% of un-
treated and 25% of treated patients.186 Upper tract and
terminal ileum biopsies were essential to the identification of
42% of patients with granulomas. In the lack of appropriate
tissue sampling, there is a risk of failing to identify granu-
lomatous inflammation. Colonic biopsies from endoscopically
bland, apparently non-affected areas should always be
included in patient evaluation.187
CD may be affected by an age gradient. There is an inverse
linear relationship between age and Crohn's colitis. Hence, the
younger the patient the more likely is the patient to have
colonic involvement. This inverse relationship is true through
age 10. In addition, pediatric patients are more likely to have
upper gastrointestinal involvement than their adult counter-
parts.188 They may display focal inflammation in the esopha-
gus, the stomach and the duodenum. Notably, lymphocytic
esophagitis, a rather recently described entity, has been found
to affect children with distal CD.189–191 Thus, biopsies from the
upper gastrointestinal tract should routinely be investigated in
pediatric patients at initial presentation of IBD.
4.4. Colorectal and small bowel cancer
Patients with CD carry an increased risk of both colorectal
and small bowel adenocarcinoma.192–196 The most important
risk factors for the development of colorectal cancer are
young age at onset, long disease duration and extensive large
bowel involvement (pancolitis), indicating a cumulative effect
of colonic inflammation (dysplasia–carcinoma sequence), as
known from patients with UC.95,197 Endoscopy with biopsy is
used for secondary prevention and the detection of dysplasia
in UC and may similarly be used in patients with CD depending
on the extent of colon involvement. With respect to small
bowel cancer, the relative risk is particularly high. Owing to
the overall rarity of the disease, however, the cumulative risk
is still low and surveillance is not recommended. Within the
small bowel, lesions most commonly affect the distal jejunum
and ileum.198,199
In IBD, dysplasia may arise within mucosa that it is in-
distinguishable from surrounding non-dysplastic mucosa
(Table 3). Hence, dysplasia has traditionally been regarded as
endoscopically “invisible”, being detectable only on random
biopsies.200 Using a random biopsy approach, sampling error
represents a well recognized limitation in the surveillance
of affected patients. In CD, the optimal number of biopsies
required for a reliable diagnosis of dysplasia has not been
established. It has been proposed, however, that 6 to 10
samples from different sites in the colon should be obtained, as
suggested for ulcerative colitis. The current recommendation is
to biopsy the colon at 10 cm intervals. Biopsies are labeled
separately so that the segment of colon fromwhich the tissue is
obtained can be subsequently identified. Rubin and colleagues
estimated that 56 non-targeted (jumbo-forceps) biopsies need
to be obtained (at each endoscopic surveillance examination)
to give 95% confidence in the detection and/or exclusion of
dysplasia. In that study 90% confidence was achieved with 33
non-targeted biopsies. 201These studies on UC have not been
replicated in Crohn's colitis. The focal nature of inflammation in
Crohn's colitis, the possibility of strictures and the prevalence
of segmental resection means that surveillance practice in UC
cannot be transferred directly to Crohn's colitis.202
5. Indeterminate, unclassified and infectious
colitis related to inflammatory bowel disease
ECCO-ESP statement 25
While “indeterminate colitis” (IC) is probably the most
commonly used terminology, no uniform definition for
this label is available in the literature and morphological
or pathological features for this diagnosis have been
confined to surgical specimens [EL1]
Labels such as “indeterminate” colitis”, “uncertain
colitis”, “inflammatory bowel disease unclassified (IBDU)”,
“CIBD-unclassified” and “chronic idiopathic inflammatory
bowel disease NOS (not otherwise specified)” are used in the
literature for patients presenting with chronic colitis without
a definitive diagnosis.
The term indeterminate colitis was first introduced in 1970
in a retrospective study of clinical and pathological (colectomy)
material from 222 patients with fulminant (n = 12) and chronic
inflammation of the colon. The aim was to see whether the
classical morphological criteria could reliably separate ulcera-
tive colitis and Crohn's colitis. Fourteen cases were categorized
as “indeterminate” because of “overlapping features” and
“data, insufficient to make a decision”.203 In 1978, Price et al.
confirmed the occurrence of “indeterminate cases” in surgical
specimens. In 27 of the 30 cases urgent surgery had been
performed. Histologic features included areas without archi-
tectural distortion to suggest longstanding disease, deep
fissuring ulcers that often went into, and sometimes through,
the muscularis propria, accompanied by transmural inflamma-
tion, although usually not with the typical lymphoid hyperplasia
associated with CD, and without overt granulomata.204 By 1980
it was clear that there is a subgroup of resection specimens that
are difficult to classify,205 mainly from patients presenting with
clinically severe disease. Subsequently, the necessity for a
correct diagnosis of CD in patients operated for severe colitis
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became very important facing the development of restorative
“pouch” operations using terminal ileal mucosa.
The introduction of endoscopy with the possibility of
obtaining endoscopic biopsies led to an evolution of the
terminology towards an integrated diagnosis based on clinical
features and endoscopy with biopsies. The term “IC” was
hence also used for patients presenting with clinical features
of chronic CIBD, with inflammation restricted to the colon and
no small bowel involvement. The term was used when
endoscopy was non-conclusive and diagnostic features for
either CD or UCwere absent on biopsies while infectious colitis
and other causes of colitis had been excluded. The tendency
to use the term IC for patients who seem to have IBD but
cannot be readily called UC or CD, became common in the
pediatric gastroenterology literature because 4 to 23% of new
onset cases in children present with an equivocal diagnosis.
This is even more prevalent in younger age (b12 years). Sixty
percent of such cases are ultimately reclassified as UC or CD.206
Diagnosis is based on a full work-up including colonoscopy with
intubation of the ileum, upper gastrointestinal endoscopy and
small bowel follow through.207,208 Whether upper gastrointes-
tinal endoscopy can sort the diagnostic problem is unclear.
The presence of focally enhanced gastritis may not be an
appropriate marker, as it can occur in both CD and UC, even in
children, although it is more frequent in CD.209 Video capsule
endoscopy revealing small bowel pathology may be helpful.210
Epidemiologists also use the term IC for patients with clear
evidence of IBD but insufficient data to make a definite
diagnosis of UC or CD, based on the clinical, endoscopic and
histologic data available.211
There are no histologic features reported in the literature
to make a positive diagnosis of IC on endoscopic biopsies. A
blinded histologic study of endoscopic biopsies from 9
segments of the colon, involving 3 experienced GI pathologists
failed to identify definite features.212 The same results were
obtained in a subsequent study of 60 cases with established
colitis involving 25 pathologists.8 Furthermore, microscopy of
endoscopic samples does not allow evaluation of features
present in the deeper layers of the bowel wall which is in
contrast with the original description of indeterminate colitis.
This is however important as CD is characterized by transmural
inflammation.
ECCO-ESP statement 26
The pathological diagnosis of indeterminate colitis
on resected specimens relies on the presence of
“overlapping features” or the absence of a “clear
diagnostic pattern”; it is not a real “positive” diagnosis
[EL1]
The general definition of IC is thus based on diagnostic
uncertainty as to whether a patient has UC or CD but the
histologic work-up can be different. To solve problems related
to the ambiguous meaning of the term IC, the working party of
the 2005 Montreal World congress of Gastroenterology
suggested to clarify the definitions.213 The proposal was
supported by the Pathology task force of the International
Organization for Inflammatory Bowel disease (IOIBD).214 The
ECCO/ESP working group for the European consensus in
pathological findings in IBD equally favors an agreement on
terminology in order to allow comparisons between different
types of studies.
Macroscopically, IC is characterized by extensive ulcera-
tions, involvement of transverse and right colon, with usually
diffuse disease (less severe in the distal colon). Microscopy
confirms extensive ulceration with a sharp transition to normal
adjacent mucosa and multiple V-shaped ulcers lacking
surrounding inflammation. Overlapping features are “severe
mucosal andwall involvement”,203 non-aggregated transmural
inflammation,204 fissures reaching the muscularis propria and
a discontinuous pattern.204,205 Diffuse mucosal disease with
normal ileum, deep mural lymphoid aggregation and nerve
hypertrophy, non-necrotizing granulomata in lymph nodes,
and anal fistula are reported in cases with non-severe chronic
disease.215
ECCO-ESP statement 27
Pathologists should avoid the diagnosis of indetermi-
nate colitis based on the evaluation of endoscopic
preoperative biopsies because of the high potential
for diagnostic error [EL5].
Instead the term inflammatory bowel disease unclassi-
fied could be used for patients with chronic colitis who
clearly have inflammatory bowel disease based on the
clinical history but macroscopy and/or endoscopic
biopsies show no definitive features of ulcerative colitis
or Crohn's disease [EL5]
The reasons for this proposal are: 1) the term IC was
originally proposed for colectomy specimens; 2) not all
diagnosticmicroscopic features can be assessed on endoscopic
biopsy samples; 3) there are no generally accepted positive
microscopic features for a diagnosis of IC on endoscopic
samples; 4) post-operative examination of resections of such
cases usually provides definitive evidence of UC or CD.216,217
Both IC and IBDU are “temporary diagnoses”. Diagnostic
uncertainty occurs more often in children. However, a histo-
logic pattern of non-diffuse acute and chronic inflammation
with architectural changes confined to the colon without a
definite classification being possible can also be observed in
adults as part of the natural history of ulcerative colitis or
secondary to treatment.24,41 Scheduled follow-up procedures
at 1 and 5 years for reconfirmation of diagnosis and disease
activity and revision of previous biopsies should be performed
in these patients. Epidemiological studies have shown that
most cases with uncertain diagnosis behave like UC.212
ECCO-ESP statement 28
Infections may be involved in triggering the onset of
inflammatory bowel disease. Intestinal super infections
may trigger flares of disease and complicate the clinical
picture [EL1]
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The relationship between infections and IBD is complex.
Infectious colitis must be considered in the differential
diagnosis. Microbes have been proposed as possible causa-
tive agents of IBD. They can be responsible for complications
such as abscesses and they have been linked with onset of
the disease and relapse of symptoms.218 Therefore it is
essential to apply the appropriate diagnostic procedures for
the identification of microorganisms in patients with IBD, at
onset and during follow-up.
ECCO-ESP statement 29
Histology is not a good tool to identify bacterial infec-
tion of the small or large intestine (EL5). This holds true
especially for Clostridium difficile infection [EL1]
C. difficile associated colitis can present with a variety of
microscopic patterns ranging from oedema, overt active colitis
without architectural abnormalities to pseudomembranous
colitis. In IBD absence of pseudomembranes in C. difficile-
associated diarrhea is noted in patients using immunosup-
pressive agents. Overall, the endoscopic finding of pseudo-
membranes is reported in 50% of C. difficile infected patients,
and is less common (13%) in IBD patients with C. difficile.
Similarly, the typical histologic findings of pseudomembranous
colitis are usually not present.219–221
ECCO-ESP statement 30
In active IBD CMV can be detected using hematoxylin
and eosin (H&E) staining, immunohistochemistry (IHC)
and quantitative tissue PCR [EL1]
In CMV infection H&E typically reveals enlarged (cytome-
galic) cells with large eosinophilic nuclear inclusions, usually
surrounded by a clear halo, and smaller cytoplasmatic
inclusions. However, stromal cells often show a less charac-
teristic picture and ganglion and degenerated cells may
imitate CMV inclusions. Specificity of H&E ranges from 92% to
100%, with low sensitivity of 10 to 87% reported. IHC improves
histologic sensitivity and specificity. It involves identification
of the CMV early antigen using monoclonal antibodies, thus
identifying more infected cells in the colon. Sensitivity ranges
from 78 to 93%. Qualitative PCR of colonic tissue can also be
used to detect viral DNA in the colon, although the significance
of a positive result in the absence of other histologic signs of
infections remains unclear. Quantitative PCR may be more
accurate, differing between infection and disease, however,
no cut off has been defined.222 CMV disease infers detection in
the organ involved.223 Semi quantitative immunohistochemis-
try, reporting the number of infected cells and/or the number
of CMV positive biopsy fragments, may have a predictive
value.223–225
6. Collagenous, lymphocytic colitis and variants
ECCO ESP statement 31
The term microscopic colitis describes a clinical patho-
logical entity characterized by three elements: A) a
clinical history of chronic watery (non-bloody) diarrhea;
B) a normal or almost normal endoscopic appearance of
the colon; C) a distinct histologic pattern. The latter can
be either that of collagenous colitis or that of lympho-
cytic colitis [EL1]
Approximately 1% of the patients presenting with chronic
diarrhea need specialized investigations including colonos-
copy. For these patients a broad spectrum of diagnoses must
be considered. Chronic non-bloody diarrhea can be due
to infections (post-infectious irritable bowel syndrome,
Spirochaetosis, miscellaneous infections such as C. difficile
and Campylobacter sp.), drugs, allergy-associated (eosino-
philic) colitis and so-called “microscopic colitis” (MC). The
term MC was introduced in 1980 for a condition characterized
by chronic diarrhea and a mild increase in inflammatory cells
in the colonic mucosa which was macroscopically normal.226
The disease was subsequently renamed as “lymphocytic
colitis” (LC) because of its histologic characteristics.227 A
few years before, a related entity with similar features but
with the additional finding of a thickened subepithelial
collagenous band had been described and named “collagenous
colitis” (CC).228 In the 1980s several studies confirmed these
observations.229–233 In 1993, a French and an American
research group suggested the use of MC as an umbrella term
to cover any form of colitis in which there were histologic but
no endoscopic or radiologic abnormalities. Later it became the
umbrella term for the two major entities known as LC and
CC.234,235 These are both clinically characterized by chronic
watery diarrhea while other conditionswith normal endoscopy
and abnormal histology may have other clinical characteris-
tics. MC is thus a distinct clinicopathologic entity in which for
the pathologists it is preferable to use the specific term
related to the condition: LC or CC. The pathogenesis is still
not completely understood and probably multifactorial. It
is suggested to represent a specific mucosal response, in
susceptible individuals to various noxious luminal agents.
These can be drugs, enteric infections or other.236
ECCO-ESP statement 32
The diagnosis of collagenous colitis on routinely hema-
toxylin and eosin stained sections is based on the
presence of a thick amorphous hyaline eosinophilic
band immediately beneath the surface epitheliumof the
mucosa. This layer has an irregular, jagged aspect of
the lower edge. The thickness is N10 μm. Its presence
is associated with inflammation [EL2]
Two elements are important for the assessment of the
collagen band: the thickness and the irregularity. There is no
842 F. Magro et al.
real consensus how thick the collagenous band should be. The
various values proposed include 7 μmormore; 10 μmor more;
10 to 15 μm; 12 μm or more, and more than 15 μm.237 Values
as thick as 70 μm have been reported.238 The average
thickness of the normal subepithelial collagen table is
approximately 3 μm.230,239 There is also no agreement among
pathologists about the “ideal method” for the assessment of
the thickness of the collagen band: histologic evaluation,
conventional measurement using a calibrated micrometer
scale or semiautomatic micrometer measurements.238 Al-
though the collagen band is usually amorphous, capillaries
and fusiform cells can be found within the material.
The fusiform cells have ultrastructural features consistent
with activated pericryptal myofibroblasts. The collagen
deposition can be patchy in distribution and the thickness can
be variable along the length of the colon.240–242 Only 66% of
biopsies from the rectosigmoid colon were diagnostic in one
study.242
A common pitfall for the diagnosis is the misinterpretation
of the basement membrane as collagen deposition in poorly
oriented, tangentially sectioned biopsies. A trichrome stain is a
useful ancillary technique because it allows the identification
of collagen. Immunohistochemistry with antibodies directed
against Tenascin is an alternative. The latter molecule is not
present in the normal adult colon. Several studies have shown
that the collagen band consists predominantly of Type VI
collagen and Tenascin, with lesser amounts of collagen Type I
and III unlike normal basement membrane which consists of
Type IV collagen.243–245 Thickening of the collagen band can be
seen in other conditions such as ischemia, diverticular disease,
mucosal prolapse, diabetes and hyperplastic polyps. In these
conditions, however, the inflammatory changes necessary for
the diagnosis of CC are not present. Amyloid colitis can also
show thickened eosinophilic material underneath the surface
epithelium. This can be identified with specific stains such as
Congo red. The density of the infiltrate within the lamina
propria and its composition can be extremely variable. Of
note, the histologic features of CC (and LC) can regress after
therapy.
ECCO-ESP statement 33
The density of the inflammatory cells in the epithelium
and lamina propria is increased in collagenous colitis.
The composition of the infiltrate is also changed.
Eosinophils may be markedly increased and are some-
times seen infiltrating crypt and surface epithelium
together with lymphocytes. The number of mast cells
and lymphocytes may also be increased. Neutrophils
are often present and may induce occasional crypt
abscesses [EL1]
The exact number of intraepithelial lymphocytes (IELs)
needed for a diagnosis of LC has not been determined. The
required number varies between 10 and 20 per 100 surface
epithelial cells (normal number = 4 to 10). In the study by
Lazenby et al.,227 there was an average of 24 lymphocytes
per 100 surface epithelial cells. The number can vary among
biopsy samples between 10 and 65 (median 30). There is no
tendency for a prominent increase in a particular segment of
the colon although inflammation may be less prominent in
the left colon. Immunohistochemical analysis shows that the
increased IELs retain the normal CD3/CD8 positive T cell
phenotype. While plasma cells are numerous, T lymphocytes
are the predominant cell type in the lamina propria.246
ECCO-ESP statement 34
The diagnosis of lymphocytic colitis is based on a
diffuse increase of intraepithelial lymphocytes (IELs)
(N20 IELs per 100 epithelial cells) in the surface
epithelium without associated thickening of the
subepithelial collagen accompanied by an increase of
lamina propria inflammatory cells [EL2]
The diagnosis of LC should be made in conjunction with
clinical, endoscopic and histologic findings. Resolving in-
fections and drug reactions can lead to similar changes.
While typical infections of the colon reveal a marked infiltrate
of neutrophils in the lamina propria with crypt abscesses,
resolving infections may have a more subtle pattern of
inflammation thatmay resemble LC because of amild increase
of IELs. However, infectious diarrhea is usually self-limited. In
addition, it can be accompanied by bloody diarrhea, endo-
scopic abnormalities and positive stool cultures.12,247 Distinc-
tion of CC and LC fromUC or CD, evenwithminimal changes, is
based on a different clinical and endoscopic setting.248
However, small series have identified patients with both a
histologic diagnosis of MC and classic IBD at different time
points.249
ECCO-ESP statement 35
In both, collagenous and lymphocytic colitis degener-
ation and/or detachment of the epithelium can be seen
[EL1]
A close association between celiac disease and LC or CC has
been observed. The association is stronger for LC. Approxi-
mately one third of all patients with celiac disease may show
histologic features of LC on biopsy while as many as one fourth
or patients with LC could have celiac disease.250–253
ECCO-ESP statement 36
The terminal ileummaybe involved inmicroscopic colitis
[EL3]
Several studies suggest that the terminal ileum can be
involved in MC. An increased terminal ileal IELs count was
found in 7 out of 14 patients with CC and 14 out of 18
patients with LC. In addition, subepithelial collagen
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deposition was found in the terminal ileum biopsies in some
patients with CC and primary ileal villous atrophy was noted
in 3 out of 14 of patients with CC and 1 out of 18 patients
with LC.254,255 CC is also occasionally associated with
collagenous gastritis and duodenitis.256
ECCO-ESP statement 37
Given the importance of the early detection of gluten
sensitivity, celiac disease should be excluded, particu-
larly in patients with lymphocytic colitis [EL1]
Overlapping features have been reported in up to 30% of
patients in some series.257–260 In addition, several variant or
atypical forms of MC have been described. The clinical
presentation is usually similar to the classic form of MC but
the histology is different. Rubio and Lindholm reported six
patients with symptoms similar to those of LC and increased
IEL count limited to the cryptal epithelium. The mean
number of IELs was 46/100 crypt epithelial cells while the
mean number for the surface was 7 IELs/100 epithelial cells.
Immunohistochemistry with CD3 and CD8 antibodies re-
vealed a classic phenotype. Special stains showed a normal
basement membrane underneath the surface epithelium. At
endoscopy the colon was essentially normal. There was no
evidence that these patients suffered from celiac disease,
IBD, or infectious colitis. The authors proposed the name
“cryptal lymphocytic colitis”.261 The distinctive histologic
features that separate “paucicellular lymphocytic colitis”
from classic lymphocytic colitis are patchiness and a lower
density of surface IELs.262 Colonic biopsies show a mild
increase of lamina propria cellularity with focal distribution
associated with an increase of IELs. Involved areas are
separated by normal mucosa. The mean surface IEL score is
11.1 per 100 epithelial cells. Some authors call this condition
“colonic epithelial lymphocytosis” or “microscopic colitis,
not otherwise specified (NOS)”. One study raises the idea
that paucicellular LC may be a separate entity with loss of
expression of CD25 and FOXP3.263 MC with giant cells is a
rare atypical form characterized by the presence of
multinucleated giant cells in an otherwise classic LC or
CC.264 Pseudomembrane formation has been reported in
association with CC. The clinical outcome of the patients is
similar to that of patients with classic CC.265 The clinical
significance of these variants has to be established.
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